Micutan (Terbinafine)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. The resulting buildup of squalene and loss of ergosterol disrupts membrane integrity, leading to fungal cell death and clearance of the infection.

The dosage of Micutan is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other individual factors. Physicians set the appropriate regimen, and patients should follow the prescribed instructions without alteration.

Safety data for terbinafine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss potential risks with the patient.

To request Micutan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The primary alternative to terbinafine is itraconazole, a triazole antifungal. Terbinafine generally offers a shorter treatment duration for nail infections and has a different safety profile, with less hepatic enzyme induction than itraconazole. Choice of therapy depends on infection type, patient tolerance and drug‑interaction considerations.

Micutan should be stored at ambient temperature, below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Micutan is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

Serious adverse events include hepatotoxicity (elevated liver enzymes, hepatitis, jaundice), severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, peripheral neuropathy, and rare blood disorders like neutropenia. Patients should seek immediate medical attention if they notice signs of liver injury, rash, or neurological symptoms.

Micutan is contraindicated in patients with known hypersensitivity to terbinafine or any component of the formulation. Caution is advised for individuals with pre‑existing liver disease, severe renal impairment, or those taking medications that strongly interact with terbinafine metabolism. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.